✦ LIBER ✦

O.6 Antisense approach for myotonic dystrophy

✍ Scribed by G. Gourdon; D. Furling; G. Bassez; J. Puymirat

Book ID: 116795074
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 47 KB
Volume: 21
Category: Article
ISSN: 0960-8966
DOI: 10.1016/j.nmd.2011.06.892

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

O02 RNA therapy approaches in myotonic d

O02 RNA therapy approaches in myotonic dystrophy

✍ C. Thornton 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 81 KB

O.7 Systemic delivery of RNase H-active

O.7 Systemic delivery of RNase H-active antisense oligonucleotides reverses RNA dominance in a mouse model of myotonic dystrophy

✍ T.M. Wheeler; A.J. Leger; S.K. Pandey; A.R. MacLeod; M. Nakamori; S.H. Cheng; C. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 47 KB

Potential involvement of ubiquinone in m

Potential involvement of ubiquinone in myotonic dystrophy pathophysiology: new diagnostic approaches for new rationale therapeutics

✍ D. Tedeschi; V. Lombardi; M. Mancuso; F. Martelli; C. Sighieri; A. Rocchi; S. To 📂 Article 📅 2000 🏛 Springer Milan 🌐 English ⚖ 35 KB

O.11 Development of systemic antisense t

O.11 Development of systemic antisense treatment in dystrophic mouse models for Duchenne muscular dystrophy

✍ A.M. Aartsma-Rus; C.L. Tanganyika-de Winter; M. van Putten; T. Karnaoek; J.C.T. 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 49 KB

In vivo comparison of 2′-O-methyl phosph

In vivo comparison of 2′-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping

✍ Hans A. Heemskerk; Christa L. de Winter; Sjef J. de Kimpe; Petra van Kuik-Romeij 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 409 KB

## Abstract ## Background Antisense‐mediated exon skipping is a putative treatment for Duchenne muscular dystrophy (DMD). Using antisense oligonucleotides (AONs), the disrupted DMD reading frame is restored, allowing generation of partially functional dystrophin and conversion of a severe Duchenne

G.P.6.01 Establishing the parameters for

G.P.6.01 Establishing the parameters for clinical trials of antisense oligonucleotide therapy in Duchenne muscular dystrophy

✍ M. Kinali; V. Arechavala-Gomeza; L. Feng; A. Glover; M. Guglieri; H. Jungbluth; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 46 KB